These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37118869)

  • 1. Lean nonalcoholic fatty liver disease: Age-dependent differences in pathology, prognosis, and liver-related events.
    Kawanaka M; Nishino K; Kawada M; Ishii K; Tanikawa T; Katsumata R; Urata N; Nakamura J; Suehiro M; Haruma K; Kawamoto H
    Hepatol Res; 2023 Sep; 53(9):829-843. PubMed ID: 37118869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease.
    Wang J; Liu J; Liu Y; Xue R; Zhan J; Jiang S; Wang L; Yan X; Xiong Y; Xia J; Yin S; Tong X; Chen Y; Li J; Huang R; Wu C
    Hepatol Res; 2023 Mar; 53(3):184-195. PubMed ID: 36317959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.
    Akyuz U; Yesil A; Yilmaz Y
    Scand J Gastroenterol; 2015 Mar; 50(3):341-6. PubMed ID: 25540973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    Hepatol Commun; 2018 Jan; 2(1):48-57. PubMed ID: 29404512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of "indeterminate score" measurements in lean nonalcoholic fatty liver disease patients from western Saudi Arabia.
    Khayyat YM
    World J Hepatol; 2021 Dec; 13(12):2150-2160. PubMed ID: 35070015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease.
    Park H; Yoon EL; Ito T; Jo AJ; Kim M; Lee J; Kim HL; Arai T; Atsukawa M; Kawanaka M; Toyoda H; Ishigami M; Yu ML; Jun DW; Nguyen MH
    JAMA Netw Open; 2023 Aug; 6(8):e2329568. PubMed ID: 37589973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease.
    Navarroza AMC; Wong SN
    Indian J Gastroenterol; 2021 Aug; 40(4):380-388. PubMed ID: 34213749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
    Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
    World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-Exome Sequencing Identifies a Variant in Phosphatidylethanolamine N-Methyltransferase Gene to be Associated With Lean-Nonalcoholic Fatty Liver Disease.
    Bale G; Vishnubhotla RV; Mitnala S; Sharma M; Padaki RN; Pawar SC; Duvvur RN
    J Clin Exp Hepatol; 2019; 9(5):561-568. PubMed ID: 31695245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors of nonalcoholic fatty liver disease in lean body mass population: A systematic review and meta-analysis.
    Alam S; Eslam M; Skm Hasan N; Anam K; Chowdhury MAB; Khan MAS; Hasan MJ; Mohamed R
    JGH Open; 2021 Nov; 5(11):1236-1249. PubMed ID: 34816009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
    Younes R; Govaere O; Petta S; Miele L; Tiniakos D; Burt A; David E; Vecchio FM; Maggioni M; Cabibi D; McLeod D; Pareja MJ; Fracanzani AL; Aller R; Rosso C; Ampuero J; Gallego-Durán R; Armandi A; Caviglia GP; Zaki MYW; Liguori A; Francione P; Pennisi G; Grieco A; Birolo G; Fariselli P; Eslam M; Valenti L; George J; Romero-Gómez M; Anstee QM; Bugianesi E
    Gut; 2022 Feb; 71(2):382-390. PubMed ID: 33541866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between the lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes in a healthy population of Northwest China: a retrospective cohort study with a 2-year follow-up period.
    Li N; Xang W; Wu S; Li D; Chang M; Xie C; Zhang MY; Tan H
    Front Endocrinol (Lausanne); 2023; 14():1173757. PubMed ID: 37435491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and risk factors of nonalcoholic fatty liver disease, high-risk nonalcoholic steatohepatitis, and fibrosis among lean United States adults: NHANES 2017-2020.
    Kalligeros M; Vassilopoulos S; Vassilopoulos A; Shehadeh F; Lazaridou I; Mylonakis E; Promrat K; Wands JR
    Ann Gastroenterol; 2023; 36(6):670-677. PubMed ID: 38023978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus.
    Cervo A; Milic J; Mazzola G; Schepis F; Petta S; Krahn T; Lebouche B; Deschenes M; Cascio A; Guaraldi G; Sebastiani G
    Clin Infect Dis; 2020 Dec; 71(10):e694-e701. PubMed ID: 32280969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Comorbid Diseases.
    Weinberg EM; Trinh HN; Firpi RJ; Bhamidimarri KR; Klein S; Durlam J; Watkins S; Reddy KR; Weiss M; Zink RC; Lok AS
    Clin Gastroenterol Hepatol; 2021 May; 19(5):996-1008.e6. PubMed ID: 32629123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum miR-4488 as a potential biomarker of lean nonalcoholic fatty liver disease.
    Shen N; Tang L; Qian Y; Pan J; Pan J; Miao H; Zhang H; Fang H; Yu X; Xing L
    Ann Transl Med; 2023 Feb; 11(4):173. PubMed ID: 36923095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.